Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

liposomal interleukin-2

A formulation in which liposomes are loaded with the cytokine interleukin-2 (IL-2). By activating cytotoxic T lymphocytes, such as lymphokine-activated killer cells, and increasing levels of the cytotoxic cytokines interferon-gamma (IFN-gamma) and transforming growth factor-beta (TGF-beta), IL-2 may exhibit antitumoral activity. Liposomal formulations of IL-2 may promote entry of the cytokine into target tumor cells and may be used as an immunoadjuvant in cancer vaccine therapy.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	interleukin-2 liposome liposome encapsulated interleukin-2
Abbreviation:	IL-2 LIPO

liposomal interleukin-2

Search NCI's Drug Dictionary